Viking Therapeutics' experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial, meeting Wall Street expectations...
March 26, 2024 -Viking Therapeutics' experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial, meeting Wall Street expectations and sending the company's shares up 15% in premarket trading on Tuesday.
Popular market leaders from Eli Lilly and Novo Nordisk are administered under-the-skin, with companies also testing oral versions that they hope will offer patients a more convenient option. California-based Viking reported weight loss of 3.3% in seven people given the highest 40-milligram dose of the drug, called VK2735, when adjusted for placebo rates, at 28 days. It helped patients lose weight by 1.1% on average at a half-strength dose. The Viking drug meets market expectations for weight loss given that Novo Nordisk's pill amycretin showed an efficacy of about 4% at the same time point, and at higher doses, said David Song, an investment partner at ETF-operator Tema ETFs. Viking said it planned to continue the trial to test higher doses of the drug in healthy or overweight volunteers, given that side effects were mild- and- moderate in severity.The data on VK2735 closely follows mid-stage results that showed an injectable version of the drug helped patients lose nearly 15% of their body weight on average. In a conference call with analysts, the company said patients who have already achieved high weight loss from an injection could transition to oral drugs to help maintain their weight. On the other hand, "if somebody didn't want to start with an injectable therapy, maybe they could start with an oral for some temporary period of time," said CEO Brian Lian. When they realize that an injected version "might generate better weight loss, it would probably reduce their resistance to transition to an injectable," he said. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Please follow us on Google to support us United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Weight-Loss Drug Amycretin Has Patients Losing 13% of Body Weight in Just 3 MonthsDigital destination for sophisticated men & women. Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle.
Read more »
San Diego's latest biotech, Contineum Therapeutics, files to go publicContineum Therapeutics filed to go public, making it San Diego's second life science IPO of 2024
Read more »
Oprah slams body shaming: ‘Making fun of my weight was a national sport’Oprah Winfrey’s TV special explored the impact weight loss drugs are having on patients, while exploring her weight struggles and experience with weight-loss medication.
Read more »
Amazon Big Spring Sale 2024: tablet deals on Pixel Tablet, Galaxy Tab A9+, and many moreDay 2 of the Big Spring Sale at Amazon is already here. Check out today's top offers!
Read more »
Viking Therapeutics' Experimental Tablet Cuts Weight in Small StudyViking Therapeutics' experimental tablet helped reduce weight by as much as 3.3% in obese patients during a small early-stage study, meeting Wall Street expectations, and...
Read more »
Viking Therapeutics stock jumps more than 25% on promising weight loss pill dataThe Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.
Read more »